Zhejiang Pharmaceutical

 

On July 14th, Zhejiang Pharmaceutical announced that it expects to achieve a net profit attributable to shareholders of 600 million to 720 million yuan in the first half of 2025, an increase of 285 million to 405 million yuan compared to the same period last year, and a year-on-year increase of 90.28% to 128.33%. Meanwhile, it is expected that the net profit attributable to the parent company, after deducting non recurring gains and losses, will be between 590 million yuan and 708 million yuan, an increase of 273 million yuan to 391 million yuan from the same period last year, and an increase of 86.27% to 123.53% year-on-year.

 

The announcement shows that the company's performance has increased in the first half of the year, mainly due to the growth in market demand and sales prices of the leading products in the life nutrition sector during the reporting period compared to the same period last year, resulting in a corresponding increase in sales revenue.

 

Shuanglu Pharmaceutical

 

On July 11th, Shuanglu Pharmaceutical announced that it expects the net profit attributable to shareholders of the listed company for the first half of 2025 to be between 100 million and 135 million yuan, with a year-on-year growth rate of 237.95% to 356.24%. However, its net profit after deducting non recurring gains and losses has experienced a significant decline, with an expected year-on-year decrease of 70.96% to 84.23%, ranging from 19 million to 35 million yuan.

 

The significant increase in net profit of Shuanglu Pharmaceutical in the first half of the year is mainly due to the significant gains from changes in fair value of trading financial assets and available for sale financial assets in non recurring gains and losses. From January to June 2025, the fair value change profit and loss of Shuanglu Pharmaceutical was approximately 110 million yuan, compared to -118 million yuan in the same period last year, with a fair value change amount of 228 million yuan.

 

Ganli Pharmaceutical

 

On July 10th, Ganli Pharmaceutical released its semi annual performance forecast for 2025, which showed that the company expects to achieve a net profit attributable to shareholders of 600 million to 640 million yuan in the first half of the year, with a year-on-year increase of 100.73% -114.12%.

 

Regarding the significant increase in net profit attributable to the parent company, Ganli Pharmaceutical stated in the announcement that it was due to a 32.6% increase in the volume of ongoing procurement agreements in 2024 compared to the previous year, coupled with a reasonable rebound in product prices, forming a synergistic effect of "both quantity and price rising".

 

WuXi AppTec

 

On July 10th, WuXi AppTec disclosed its performance forecast, expecting to achieve a revenue of approximately 20.799 billion yuan in the first half of the year, a year-on-year increase of approximately 20.64%,. After adjustment, the net profit attributable to the shareholders of the parent company is expected to be approximately 6.315 billion yuan, with a year-on-year increase of approximately 44.43%; The net profit attributable to the shareholders of our company is expected to be approximately 8.561 billion yuan, a year-on-year increase of approximately 101.92%; The expected basic earnings per share are approximately 3.01 yuan per share, with a year-on-year increase of approximately 106.16%.

 

WuXi AppTec stated that the expected increase in performance in the first half of the year is mainly due to the company's focus on the certainty of customer empowerment needs, continuous expansion of new capabilities, construction of new production capacity, continuous optimization of production processes, and improvement of operational efficiency, driving sustained and steady business growth.

 

Hanyu Pharmaceutical

 

Hanyu Pharmaceutical is expected to achieve a net profit of 142 million to 162 million yuan in the first half of 2025, with a year-on-year increase of 1470% -1663%, achieving a turning point from a loss to a profit in the same period of 2024.

 

Its announcement stated that this is mainly due to the continuous growth of global market demand. In December 2024, Liraglutide Injection was approved by the US FDA and achieved sales, the export volume of active pharmaceutical ingredients continued to increase, the market competitiveness of the company's products, and strict cost control. The high operating profit margin of the international business further promoted the overall profitability of the company.

 

 

In addition to the aforementioned pharmaceutical companies, companies such as Beida Pharmaceutical, Kanghong Pharmaceutical, Huadong Pharmaceutical, and Junshi Biotechnology are expected to see a year-on-year increase of over 100% in their reported net profit attributable to the parent company in 2025. Analysts believe that the impressive performance of these pharmaceutical companies not only reflects their positive achievements in adjusting business strategies, cost control, and market expansion, but also implies that the pharmaceutical industry has ushered in new development opportunities driven by macro factors such as policy support and demand growth.

 

However, it should be noted that many pharmaceutical companies expect to incur losses in the first half of 2025. This reflects that the development of the pharmaceutical industry is still full of uncertainty, and related enterprises need to continuously improve their innovation capabilities, market adaptability, and adaptability to changes in industry policies in the future.